All In Biotech

NDA 022416 · Sumitomo Pharma Am

Aptiom

Eslicarbazepine Acetate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Nov 8, 2013

Approved uses

4

Original approval plus efficacy supplements

Registered trials

62

14 Phase 3, 1 recruiting

FAERS reports

3,321

2,320 serious, 98 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2023.

APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. ( 1 )

Mechanism: APTIOM is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • APTIOM · ESLICARBAZEPINE ACETATE 600MG · TABLET, ORAL · Prescription · TE AB
  • APTIOM · ESLICARBAZEPINE ACETATE 200MG · TABLET, ORAL · Prescription · TE AB
  • APTIOM · ESLICARBAZEPINE ACETATE 800MG · TABLET, ORAL · Prescription · TE AB
  • APTIOM · ESLICARBAZEPINE ACETATE 400MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Eslicarbazepine" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure1,014
  • off label use324
  • drug ineffective306
  • dizziness231
  • somnolence193
  • hyponatraemia172
  • fatigue158
  • headache139
  • generalised tonic-clonic seizure118
  • fall117
  • nausea106
  • therapy interrupted100

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20113
20124
20134
201434
2015123
2016164
2017247
2018326
2019397
2020288
2021397
2022270
2023266
2024343
2025267
2026187

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aptiom (Eslicarbazepine Acetate)

2024 spending

$144M

Beneficiaries

8,265

83,810 claims

Per beneficiary

$17,432

$42.93 per unit

View as table
YearSpending
2020$120,378,678
2021$124,002,820
2022$131,375,197
2023$142,014,028
2024$144,071,383

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 122 on PubMed

Sponsor: Sumitomo Pharma Am

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.